Scinai Immunotherapeutics reported a gross margin of -272.17% and a net margin of -466.52% for the quarter ended Jun 2026. These financial ratios cover 41 quarters of results from Mar 2015 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Mar2015 | Jun2015 | Dec2015 | Mar2016 | Jun2016 | Dec2016 | Mar2017 | Dec2017 | Mar2018 | Jun2018 | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||||||||||||||||||||||||||||||
| Gross Margin | -148.21% | -81.07% | 38.91% | -801.07% | -228.63% | -272.17% | |||||||||||||||||||||||||||||||||||
| EBT Margin | 6,223.21% | -1,098.54% | -267.58% | -1,173.80% | -504.50% | -466.52% | |||||||||||||||||||||||||||||||||||
| EBIT Margin | -1,440.48% | -1,098.54% | -267.58% | -1,173.80% | -504.50% | -466.52% | |||||||||||||||||||||||||||||||||||
| EBITDA Margin | -1,440.48% | -1,098.54% | -267.58% | -1,173.80% | -504.50% | -466.52% | |||||||||||||||||||||||||||||||||||
| Operating Margin | -1,440.48% | -1,098.54% | -267.58% | -1,173.80% | -504.50% | -466.52% | |||||||||||||||||||||||||||||||||||
| Net Margin | 6,223.21% | -1,098.54% | -267.58% | -1,173.80% | -504.50% | -466.52% | |||||||||||||||||||||||||||||||||||
| FCF Margin | -1,210.71% | -522.33% | -176.11% | -818.72% | -297.14% | -511.30% | |||||||||||||||||||||||||||||||||||
| Efficiency | |||||||||||||||||||||||||||||||||||||||||
| Assets AverageAssets Avg. | 0.03B | 0.02B | 0.02B | 0.03B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.01B | 0.01B | 0.01B | 0.01B | 0.02B | |||||||||||||||||||||||||||
| Invested CapitalInvested Cap. | 0.02B | 0.03B | 0.01B | 0.00B | 0.02B | 0.02B | 0.02B | 0.02B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.00B | 0.01B | 0.01B | ||||||||||||||||||||||||
| Asset Utilization RatioAsset Util. | 0.10 | 0.10 | |||||||||||||||||||||||||||||||||||||||
| Leverage & Solvency | |||||||||||||||||||||||||||||||||||||||||
| Interest Coverage RatioInterest Cover | 2.88 | 2.94 | 4.02 | 3.55 | 0.90 | -0.35 | 0.88 | ||||||||||||||||||||||||||||||||||
| Debt Ratio | 0.80 | 0.87 | 0.22 | 0.01 | 0.77 | 0.94 | 1.17 | 1.00 | 1.11 | 1.14 | 1.33 | 0.02 | 0.02 | 0.02 | -0.60 | 0.02 | 0.02 | ||||||||||||||||||||||||
| Times Interest Earned | 2.88 | 2.94 | 4.02 | 3.55 | 0.90 | -0.35 | 0.88 | ||||||||||||||||||||||||||||||||||
| Valuation | |||||||||||||||||||||||||||||||||||||||||
| Price to EarningsP/E | -0.00B | -0.00B | 652.38 | -0.00B | 0.00B | 378.46 | -153.70 | 890.59 | -713.76 | -156.32 | -199.93 | 499.93 | -87.76 | 61.28 | -505.09 | -585.35 | -335.04 | -215.79 | -108.80 | ||||||||||||||||||||||
| Price to SalesP/S | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 507.58 | |||||||||||||||||||||||||||||||||||
| Price to BookP/B | 0.00B | 0.00B | -0.00B | 0.00B | 0.00B | -0.00B | -589.90 | -260.43 | -424.54 | -241.85 | -188.40 | -70.88 | 64.05 | 114.56 | 93.59 | 81.83 | 45.26 | 19.90 | |||||||||||||||||||||||
| Enterprise Value | 13.20B | 10.14B | 13.45B | 12.35B | 8.67B | 5.43B | 2.22B | 2.82B | 1.84B | 1.13B | 1.10B | 0.96B | 0.51B | 0.64B | 1.14B | 0.92B | 0.73B | 0.66B | 0.53B | 0.23B | |||||||||||||||||||||
| EV to EBIT | -0.00B | -0.00B | 387.22 | -0.00B | -0.00B | 0.00B | 733.90 | 886.09 | -708.28 | -536.93 | -603.40 | 497.43 | -87.19 | -264.34 | -504.16 | -585.35 | -334.52 | -214.59 | -107.47 | ||||||||||||||||||||||
| EV to EBITDA | -0.00B | -0.00B | 387.22 | -0.00B | -0.00B | 0.00B | 733.90 | 886.09 | -708.28 | -536.93 | -603.40 | 497.43 | -87.19 | -264.34 | -504.16 | -585.35 | -334.52 | -214.59 | -107.47 | ||||||||||||||||||||||
| Market Capitalization | 13.24B | 10.15B | 13.47B | 12.37B | 8.68B | 5.44B | 2.23B | 2.84B | 1.85B | 1.14B | 1.11B | 0.96B | 0.52B | 0.64B | 1.14B | 0.92B | 0.74B | 0.66B | 0.53B | 0.23B | |||||||||||||||||||||
| Price to FCFP/FCF | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -929.39 | -741.18 | -519.01 | -0.00B | -659.73 | -294.69 | -315.01 | -0.00B | -889.36 | -480.34 | -366.38 | -99.27 | ||||||||||||||||||||||
| EV to FCF | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -924.69 | -735.49 | -512.55 | -0.00B | -656.43 | -292.77 | -314.50 | -0.00B | -889.36 | -479.61 | -364.34 | -98.06 | ||||||||||||||||||||||
| EV to CFO | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -922.88 | -639.08 | -507.94 | -897.96 | -655.53 | -291.78 | -313.88 | -0.00B | -881.67 | -478.67 | -363.59 | -93.60 | ||||||||||||||||||||||
| Return Ratios | |||||||||||||||||||||||||||||||||||||||||
| Return on Sales [ROS]ROS | -1,440.48% | -1,098.54% | -267.58% | -1,173.80% | -504.50% | -466.52% | |||||||||||||||||||||||||||||||||||
| Return on Capital Employed [ROCE]ROCE | 59.70% | 145.75% | -3.20% | 22.59% | 29.30% | 8.54% | -20.52% | -29.94% | -55.19% | -67.40% | -78.18% | -71.24% | -55.29% | ||||||||||||||||||||||||||||
| Return on Assets [ROA]ROA | 35.53% | 155.81% | 1.26% | 19.80% | 2.04% | -110.41% | -67.94% | -78.24% | -105.28% | 7.18% | 32.96% | -58.14% | -48.19% |